Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Indoximod combined with chemotherapy in newly diagnosed AML patients

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.12.18
Views: 748

Dr Ashkan Emadi - University of Maryland Medical Centre, Maryland, USA

Dr Ashkan Emadi speaks to ecancer at ASH 2018 about the results from a trial looking at indoximod combined with chemotherapy in newly diagnosed AML patients.

He explains that the intention of this phase 1 study is to measure the safety and tolerability of indoximod there was found to be minimal toxicity and adverse events were consistent with the backbone of chemotherapy treatment.

Dr Emadi reports that the study has allowed them to find the recommended dose and that first clinical signs are promising, with approximately 70% of patients achieving complete remission.

Related videos

18.06.19

no rating
Cancer care in Latin America

follow us

Core Surgical Training


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation